FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3139249056> ?p ?o ?g. }

• W3139249056 abstract "Abstract Background Our previous studies showed that GV1001 has various protective effects against β-amyloid and other stressors. Based on these findings, we hypothesized that GV1001 might have beneficial effects in patients with Alzheimer’s disease (AD). Methods A phase 2, double-blind, parallel-group, placebo-controlled, 6-month randomized clinical trial was performed to evaluate the safety and efficacy of subcutaneously administered GV1001. Between September 2017 and September 2019, 13 centers in South Korea recruited participants. A total of 106 patients were screened, and 96 patients with moderate-to-severe AD were randomized 1:1:1 to the placebo (group 1, n = 31), GV1001 0.56 mg (group 2, n = 33), and 1.12 mg (group 3, n = 32) groups. GV1001 was administered every week for 4 weeks (4 times), followed by every 2 weeks until week 24 (10 times). The primary endpoint was the change in the Severe Impairment Battery (SIB) score from baseline to week 24. The key secondary efficacy endpoints were the change in the Clinical Dementia Rating Sum of Box (CDR-SOB), Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL), Neuropsychiatric Inventory (NPI), Mini-Mental State Examination, and Global Deterioration Scale scores. The safety endpoints were also assessed based on adverse events, laboratory test results, vital signs, and other observations related to safety. Results Group 3 showed less decrease in the SIB score at 12 and 24 weeks compared with group 1 ( P < 0.05). These were not significantly observed in group 2. Among the secondary endpoints, only the NPI score showed significantly better improvement in group 2 than in group 3 at week 12; however, there were no other significant differences between the groups. Although the ADCS-ADL and CDR-SOB scores showed a pattern similar to SIB scores, a statistically significant result was not found. Adverse events were similar across all three groups. Conclusions The results indicate that GV1001 1.12 mg met the primary endpoint of a statistically significant difference. GV1001 was well tolerated without safety concerns. This study warrants a larger clinical trial. Trial registration ClinicalTrials.gov NCT03184467 . Registered on June 12, 2017." @default.
• W3139249056 created "2021-03-29" @default.
• W3139249056 creator A5013293945 @default.
• W3139249056 creator A5019254683 @default.
• W3139249056 creator A5020144229 @default.
• W3139249056 creator A5023800103 @default.
• W3139249056 creator A5034111842 @default.
• W3139249056 creator A5041486786 @default.
• W3139249056 creator A5042571833 @default.
• W3139249056 creator A5047552330 @default.
• W3139249056 creator A5051680529 @default.
• W3139249056 creator A5054261442 @default.
• W3139249056 creator A5062304322 @default.
• W3139249056 creator A5067297230 @default.
• W3139249056 creator A5069995774 @default.
• W3139249056 creator A5079352790 @default.
• W3139249056 creator A5081987635 @default.
• W3139249056 creator A5083363274 @default.
• W3139249056 date "2021-03-26" @default.
• W3139249056 modified "2023-10-18" @default.
• W3139249056 title "Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial" @default.
• W3139249056 cites W1644143258 @default.
• W3139249056 cites W173790180 @default.
• W3139249056 cites W1987294642 @default.
• W3139249056 cites W1991952617 @default.
• W3139249056 cites W1996776294 @default.
• W3139249056 cites W2001334299 @default.
• W3139249056 cites W2028466425 @default.
• W3139249056 cites W2048880420 @default.
• W3139249056 cites W2050458545 @default.
• W3139249056 cites W2052742260 @default.
• W3139249056 cites W2058112065 @default.
• W3139249056 cites W2091711919 @default.
• W3139249056 cites W2092356280 @default.
• W3139249056 cites W2111963393 @default.
• W3139249056 cites W2115017507 @default.
• W3139249056 cites W2129152730 @default.
• W3139249056 cites W2132806643 @default.
• W3139249056 cites W2163169257 @default.
• W3139249056 cites W2413937595 @default.
• W3139249056 cites W2437840001 @default.
• W3139249056 cites W2766931716 @default.
• W3139249056 cites W2768476406 @default.
• W3139249056 cites W2769095960 @default.
• W3139249056 cites W2775750683 @default.
• W3139249056 cites W2789865159 @default.
• W3139249056 cites W2798054687 @default.
• W3139249056 cites W2905504149 @default.
• W3139249056 cites W2907504502 @default.
• W3139249056 cites W2908395171 @default.
• W3139249056 cites W2960505072 @default.
• W3139249056 cites W2970537246 @default.
• W3139249056 cites W2992893037 @default.
• W3139249056 cites W3048901815 @default.
• W3139249056 cites W3107395714 @default.
• W3139249056 doi "https://doi.org/10.1186/s13195-021-00803-w" @default.
• W3139249056 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7995588" @default.
• W3139249056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33771205" @default.
• W3139249056 hasPublicationYear "2021" @default.
• W3139249056 type Work @default.
• W3139249056 sameAs 3139249056 @default.
• W3139249056 citedByCount "10" @default.
• W3139249056 countsByYear W31392490562022 @default.
• W3139249056 countsByYear W31392490562023 @default.
• W3139249056 crossrefType "journal-article" @default.
• W3139249056 hasAuthorship W3139249056A5013293945 @default.
• W3139249056 hasAuthorship W3139249056A5019254683 @default.
• W3139249056 hasAuthorship W3139249056A5020144229 @default.
• W3139249056 hasAuthorship W3139249056A5023800103 @default.
• W3139249056 hasAuthorship W3139249056A5034111842 @default.
• W3139249056 hasAuthorship W3139249056A5041486786 @default.
• W3139249056 hasAuthorship W3139249056A5042571833 @default.
• W3139249056 hasAuthorship W3139249056A5047552330 @default.
• W3139249056 hasAuthorship W3139249056A5051680529 @default.
• W3139249056 hasAuthorship W3139249056A5054261442 @default.
• W3139249056 hasAuthorship W3139249056A5062304322 @default.
• W3139249056 hasAuthorship W3139249056A5067297230 @default.
• W3139249056 hasAuthorship W3139249056A5069995774 @default.
• W3139249056 hasAuthorship W3139249056A5079352790 @default.
• W3139249056 hasAuthorship W3139249056A5081987635 @default.
• W3139249056 hasAuthorship W3139249056A5083363274 @default.
• W3139249056 hasBestOaLocation W31392490561 @default.
• W3139249056 hasConcept C126322002 @default.
• W3139249056 hasConcept C142724271 @default.
• W3139249056 hasConcept C168563851 @default.
• W3139249056 hasConcept C197934379 @default.
• W3139249056 hasConcept C203092338 @default.
• W3139249056 hasConcept C204787440 @default.
• W3139249056 hasConcept C27081682 @default.
• W3139249056 hasConcept C2779134260 @default.
• W3139249056 hasConcept C2779483572 @default.
• W3139249056 hasConcept C2780906993 @default.
• W3139249056 hasConcept C535046627 @default.
• W3139249056 hasConcept C71924100 @default.
• W3139249056 hasConceptScore W3139249056C126322002 @default.
• W3139249056 hasConceptScore W3139249056C142724271 @default.
• W3139249056 hasConceptScore W3139249056C168563851 @default.
• W3139249056 hasConceptScore W3139249056C197934379 @default.
• W3139249056 hasConceptScore W3139249056C203092338 @default.
• W3139249056 hasConceptScore W3139249056C204787440 @default.

• next